Atipamezole hydrochloride is a selective and competitive α2-adrenergic receptor antagonist primarily used in veterinary medicine to reverse sedation and anesthesia in animals, especially dogs, following surgical procedures; it reduces sedation, lowers blood pressure, increases heart and respiratory rates, and attenuates analgesia induced by α2-adrenergic agonists such as medetomidine; it is also under clinical investigation for potential use as an antihypertensive and antidiabetic agent in humans; additionally, it shows therapeutic potential in the treatment of asthma, obesity, migraine, age-related memory impairment, and prevention of postoperative ileus after abdominal surgery; low doses have demonstrated beneficial effects on alertness, selective attention, planning, learning, and recall in experimental animals.